Oral involvement in mycosis fungoides is unusual and portends a poor prognosis. The clinical findings of three new cases are described along with a differential diagnosis and review of the literature. For brevity, only one patient is discussed in detail below whereas the other two cases are solely described in table form. The patient had a four-year history of mycosis fungoides before developing an exophytic tongue tumor. He was treated with local electron beam radiation and is disease-free to date while being on maintenance therapy with oral bexarotene. Analysis of the data collected from our review of the literature and the present cases reveal key insights.
One of the most common T-cell lymphomas is mycosis fungoides (MF). It is a malignant, insidious, cutaneous, extranodal non-Hodgkin’s lymphoma (NHL) [
Oral cavity involvement in MF is rare, found in less than 1% of patients. Interestingly, autopsy studies suggest up to 13% involvement [
We have expanded on our previous case series on oral MF (20) to include three new cases that were selected from the electronic medical records of The University of Texas MD Anderson Cancer Center (UTMDACC). The patients were treated at UTMDACC over periods from 2005 to present (Case 1), 2005 to 2008 (Case 2), and 2015 to present (Case 3).
A 63-year-old white man (Case 1) presented in 2005 with exfoliative erythroderma. He stated that he was diagnosed with a rash localized to his right hand three years earlier. Over the course of one and a half years, his lesions spread widely. On presentation, he had 90% body surface area (BSA) involvement with a 3 : 1 ratio of plaque to patch. His skin exhibited indurated erythematous papular rash that was confluent over the upper and lower extremities with skip areas on the abdomen and relative sparing of the groin.
Flow cytometry revealed 30 × 109/L CD4 cells and 96% CD4+/CD26− cells. Biopsy of the tumor showed MF with large cell transformation.
The patient received numerous systemic treatments including (1) vorinostat 400 mg daily that improved his pruritus but was accompanied by intolerable side effect of diarrhea and overall lack of response in the skin, (2) forodesine with minor partial response, (3) combined modality with interferon-alpha plus bexarotene and extracorporeal photophoresis, (4) total body skin electron beam radiation that effectively cleared his skin temporarily, and (5) alemtuzumab with which he achieved durable near-complete remission.
After these treatments, roughly four years after initial presentation, the patient presented with a rapidly growing tumor on his tongue measuring 2.0 × 2.0 × 2.5 cm with a central cleft (Figure
Mycosis fungoides tumor of the patient’s tongue measuring 2.0 × 2.0 × 2.5 cm with a central cleft prior to treatment. The tumor was responsive to local electron beam radiation and maintenance bexarotene.
(a) Fungating lesion of the tongue shows a dense lymphoid infiltrate lined by the squamous epithelium of the oral mucosa. The infiltrate permeates into underlying skeletal muscle of tongue. Hematoxylin and eosin, ×40. (b) The infiltrate is composed of large cells with vesicular nuclei and prominent nucleoli. Atypical mitoses are also observed. Hematoxylin and eosin, ×1000.
Immunohistochemistry shows that the large neoplastic cells are positive for CD3 (a) and CD30 (b). Immunohistochemistry with hematoxylin counterstain; ×40 (a) and ×100 (b).
Lymphomatous lesions of the oropharynx in MF are becoming increasingly recognized in the literature. Presentation is heterogeneous, ranging from depressed ulcerations and red or white patches to exuberant outgrowth of tumors. This presents a diagnostic challenge to the uninitiated clinician. The differential diagnosis of various benign and malignant oral lesions is reviewed (Table
Differential diagnosis of oral tumors.
Disease | Oral lesion description | Diagnostic clues |
---|---|---|
Malignancy/premalignancy | ||
Squamous cell papilloma | Discrete exophytic papillary lesions (verruca): occur at any intraoral site | History of human immunodeficiency virus infection; association with cutaneous warts on fingers |
Squamous cell carcinoma | Nonhealing ulcers, papules, or plaques: occur most frequently at the floor of the mouth and soft palate | History of tobacco and alcohol consumption; mechanical trauma from ill-fitting dentures |
|
||
Mesenchymal neoplasms and tumor-like lesions | ||
Fibrous and vascular overgrowths | Discrete lesions of cheek or tongue | History of chronic irritation, usually from some tooth-related cause or chronic cheek/tongue biting |
Pyogenic granuloma | Exuberant overgrowths usually at the gingiva but can occur at any intraoral site | May bleed spontaneously or following irritation due to extreme vascularity |
|
||
Odontogenic tumors and cysts | ||
Ameloblastoma | Oral swellings occurring on the mandible that typically produce multicystic appearance on radiograph | Painless and slow growing; untreated, may reach substantial size |
Odontogenic cysts | Oral swellings arising adjacent to teeth that usually produce a well-demarcated cyst on radiograph | Painless and slow growing |
Data from the literature where oral mycosis fungoides was identified before death. An asterisk denotes that the value was not stated or unknown.
Author | At onset of MF | At onset of oral lesion | At death | Time to death from onset of oral lesion (yr.) | Sex | Stage | Cutaneous involvement | Extracutaneous involvement | Lymph node involvement | Multiple sites of oral involvement | Presence of GI involvement | Lesion type | Location of oral lesion(s) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age | At onset of oral lesion | ||||||||||||
Laskaris | 52 | 65 | 65.2 | 0.2 | F | IIb | + | + | + | + |
|
|
Buccal mucosa, lips |
Crane | 70 | 73.5 |
|
|
F | IIa | − | − | − | − | − |
|
Gingiva |
Yao | 54 | 57.8 | 59.1 | 1.3 | M | Ib | + |
|
|
+ |
|
Patch | Gingiva, buccal mucosa |
Brousset | 47 | 50 | 52 | 2 | F | Ib | + | − | − | − | − | Tumor | Lingual margin |
Vicente | |||||||||||||
Case 1 | 51 | 59 | 59.5 | 0.5 | F | IIb | + | − | − | + |
|
Plaque | Hard palate, mandibular gingiva |
Case 2 | 72 | 77 | 77.5 | 0.5 | F | IIb | + |
|
|
− |
|
Plaque | Hard palate |
Kasha | |||||||||||||
Case 1 | 65 | 66 | 67.2 | 1.2 | M | IIb | + | − | − | − | − | Plaque | Dorsal tongue |
Case 2 | 62 | 80 | 81 | 1 | M | IIa | + | − | + | + | + | Plaque | Tongue, esophagus |
Evans | 52 | 65 | 66.2 | 1.2 | F | Ib | + | − |
|
+ |
|
Plaque | Dorsal tongue, Lateral tongue |
Barnett | 39 | 69 | 69.2 | 0.2 | M | IIb | + |
|
|
+ |
|
Plaque | Palate, tongue, mucosa, gingiva, pharynx |
Cohn | 50 | 52.5 |
|
|
M | IIb | + | + | + | + |
|
Plaque | Hard palate, buccal mucosa, tongue |
Damm | 68 | 68 |
|
|
M | IIb | + | − | − | + | − |
|
Hard palate, soft palate, alveolar ridge |
Whitbeck | 68 | 72 | 72.6 | 0.6 | M | IVb | + | + | − | + | − | Tumor | Hard palate and, later, tongue |
Ellams | 52 | 52 | 52.3 | 0.3 | F | Ib | − | − |
|
+ |
|
Tumor | Gingiva, buccal mucosa, palate |
Reynolds | 60 | 75.5 | 76.7 | 1.2 | F | Ib | + | − |
|
+ |
|
Patch | Tongue, hard palate |
Wright | 60 | 61.5 | 62.7 | 1.2 | M | IVb | + | + | − | + |
|
Patch | Hard palate, upper gingiva |
Sirois | |||||||||||||
Case 1 | 71 | 75 | 76 | 1 | M | IVa | + |
|
|
+ |
|
|
Gingiva, palate, tongue, lip, buccal mucosa, tonsil |
Case 2 | 44 | 57 | 58 | 1 | M | III | + |
|
|
− |
|
|
Tongue |
Case 3 | 46 | 49 | 50 | 1 | M | IVa | + |
|
|
+ |
|
|
Gingiva, tongue |
Case 4 | 71 | 74 | 75 | 1 | M | IIb | + |
|
|
+ |
|
|
Gingiva, palate |
Case 5 | 62 | 66 | 69 | 3 | F | IIb | + |
|
|
+ |
|
|
Gingiva, palate |
Case 6 | 51 | 53 | 56 | 3 | F | IVa | + |
|
|
− |
|
|
Gingiva |
Case 7 | 67 | 73 | 81 | 8 | F | Ib | − |
|
|
− |
|
|
Gingiva |
Case 8 | 43 | 51 | 53 | 2 | M | III | + |
|
|
− |
|
|
Tongue |
McBride |
|
63 | 63.1 | 0.1 | F | IIa | + |
|
|
− |
|
Tumor | Dorsal tongue |
Harman |
|
57 | 57.6 | 0.6 | M | IIb | + | − | − | + | − |
|
Gingiva, palate |
Cawley | |||||||||||||
Case 1 | 72 | 72 | 74 | 2 | M | Ib | + | + | − | − | − |
|
Hard/soft palate, tonsils |
Case 2 | 65 | 65 | 65.0 | 0.04 | M | IIb | + | + | + | + | − | Tumor | Labial commissure, tongue |
Postorino et al. |
|
60 |
|
|
M | IIb | + | − | + | − | − | Plaque | Mucosa |
Corbett et al. |
|
|
|
|
F | IIb | + | − | − | + | − | Tumor | Soft palate, throat |
Wain et al. |
|
|
|
|
M | Ib | + | − | − | + | − | Plaque | Soft palate, tongue, lips |
Wahie et al. | 60 | 69 |
|
|
M | Ia | − | − | − | + | − |
|
Suprahyoid region, epiglottis |
Viswanathan | 69 | 69 |
|
|
M | Ia | + | − | − | + | − |
|
Tongue, soft palate |
Luigetti et al. | 27 | 38 |
|
|
F |
|
+ | + | + | + | − | Plaque | Lip, mucosa, tongue, pharynx |
Goldsmith et al. | 44 | 64 |
|
|
F |
|
+ | − | − | − | − | Plaque | Hard palate |
Le et al. | 32 | 36 |
|
|
M | IIb | + | + | + | − | − | Tumor | Tonsil |
Tillman et al. | 60 |
|
|
M |
|
|
|
|
|
|
|
| |
Chua et al. | 80 | 80.7 |
|
|
M | Ib | + | − | − | − | − | Tumor | Hard palate, gingiva, mucosa |
Gomez | |||||||||||||
Case 1 | 35 | 45 | 45.5 | 0.5 | F | IIb | + | − | − | + | − | Tumor | Tongue, uvula, oropharynx |
Case 2 | 66 | 70 |
|
|
F | Ib | + | − | − | + | − |
|
Uvula, soft palate, tonsils |
May | |||||||||||||
Case 1 |
|
40 |
|
|
F | Ia | + | − | − | − | − | Tumor | Tongue |
Case 2 | 44 | 44 |
|
|
M |
|
− | − | − | − | − |
|
Tongue |
Present report | |||||||||||||
Case 1 | 60 | 74 |
|
|
M | IVb | + | + | − | − | − | Tumor | Tongue |
Case 2 | 50 | 55 | 55.7 | 0.7 | M | IVb | + | + | − | + | − | Tumor | Palate, uvula |
Case 3 | 35 | 38 |
|
|
M | IVb | + | + |
|
+ | + | Ulcer | Tongue, palate |
MF is classically divided into three progressive, often overlapping, stages: patch, plaque, and tumor. Clinically and histopathologically, patch stage MF is commonly misdiagnosed as psoriasis. Lesions appear erythematous and sometimes scaly usually responding to topical steroids, the mainstay treatment [
During the plaque and tumor stages, lesions present a much more characteristic histologic picture. There are a dense polymorphous infiltrate and characteristic epidermotropism. Malignant cells called Sezary cells may be seen in the peripheral blood and subsequently may spread to lymph nodes. Sezary cells can be identified in peripheral blood by flow cytometry immunophenotype [
To our knowledge, there are 42 reported cases of oral MF (Table
At time of oral lesion diagnosis, 33% of patients had stage IB disease or lower and 11% had no active cutaneous disease. Most commonly, patients presented with oral lesions on the palate (
Our patient is remarkable in that he is in complete remission seven years after onset of oral lesion, which defies the median time of one year from diagnosis of oral lesion to death. Further, our patient had large cell transformation, which carries additional poor prognosis [
The authors declare that they have no competing interests.